This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vitravene

Ionis Pharmaceuticals, Inc.

Drug Names(s): Fomivirsen Sodium Intravitreal Injectable

Description: Vitravene (fomivirsen sodium intravitreal injectable, formerly Isis-2922) is a phosphorothioate oligonucleotide that inhibits human cytomegalovirus (HCMV) replication. It became the first antisense compound to be approved for marketing in the United States on August 26, 1998. It is specifically indicated for the local treatment of CMV retinitis in patients with AIDS, who are intolerant of or have a contraindication to other treatments for CMV retinitis or who were insufficiently responsive to previous treatments for CMV retinitis.

Partners: Novartis AG


Vitravene News

Pink Sheet Isis Vitravene


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug